The SIRIUS missions are the latest spaceflight analogs NASA is utilizing to help us understand the risks of travel further into the solar system.

IN MEDIA KG, a leader in the digital software industry proudly brings their Photo Editing Software for Windows 10, 8 and 7.

Audition registration for NJYS' 15 ensembles including strings, winds, percussion, jazz, chamber music, and three full orchestras is available online April 1-May 10. Audition requirements and more information can be found at www.NJYS.org.

Screening Also Slated for Women's Film Festival

Dozens of convention appearances, free merchandise and cross-country theatrical screenings of classic horror films in 2020!

CEO, Frank Lunn and Founder/Animator Jae Chang launch new digital business with roots in YouTube fame.

3D Bourne is a fun app that will allow you to generate a 3D cartoon using artificial intelligence, see it live on your table and interact with it by making it walk, run or jump.

GRE Alpha Customers will Remain Unaffected by China Tariffs

Fort Worth-Based Salon Suite Rental Chain Texts Good News to Stylists in Midst of Government-Mandated Coronavirus Shutdown

Washington, DC Website Support and Digital Agency Offering Reduced-rate Support Packages to Nonprofits in Need of Assistance for Website Maintenance or Digital Marketing Support.

EMRIS International opened its doors for pre-launch with its flagship CBD Line - Synergy, a premium THC Free, Hemp Derived CBD Oil with several potency levels and has been widely supported by thousands of new customers.

Ecommerce Retailer MENSITALY.COM Discusses Latest Trends And The Growing Global Market For Men's Suits and Men's Clothing

Developed by medical uniform leader Strategic Partners Inc (SPI), Certainty SmartBoost infuses machine-washable fabrics with protection against bacteria that cause odors and degrade fabric.

Rayward Apparel debuts new collection of sun protective clothing, compromising neither comfort nor performance in the process.

Amid COVID-19 quarantine, creativity reigns supreme

This free, 40 page online publication includes case studies, helpful articles and content on over 80 companies.

Shareholders will be ecstatic, with their stake up 30% over the past week following ObsEva SA's (NASDAQ:OBSV) latest...

(Bloomberg) -- Wall Street’s biggest firms are divided on where markets are heading to next.While most risk assets are well off their mid-March lows, when uncertainty about the global impact of the coronavirus outbreak was at its peak, there is little consensus on what is to follow. At the core of the debate is the long-term effectiveness of the massive stimulus from central banks and governments.When $8 Trillion in Global Fiscal Stimulus Still Isn’t EnoughCitigroup Inc., for one, doesn’t get the “puzzling” rise in stocks.“Extensive policy response, led by ample liquidity provided by central banks, likely contributed to the move in the markets,” economists including Igor Cesarec and Catherine Mann wrote in a note Thursday. “However, since it is not clear that markets can be propped up indefinitely, caution is warranted. Risk assets could be fragile once the cold, hard economic reality hits again.”On the other hand, JPMorgan Chase & Co. sees the stock market advance as justified -- and one which can continue.“While the collapse in economic activity is historic, so too is the global policy response to cushion the impact and support a recovery,” strategists led by Marko Kolanovic wrote in a note Thursday. “We expect risky assets to continue to recover as economies reopen and given the unprecedented policy support, though we expect a moderation in the pace of gains.”Read about JPMorgan’s call in late March that markets were probably past the worst.The MSCI AC World Index has climbed about 25% since March 23 as investor sentiment warmed toward a slew of worldwide policy measures to offset the economic impact of the pandemic. The global gauge had fallen as much as 34% from its February high, when concerns about the virus reached a peak.Looking ForwardGoldman Sachs Group Inc. and Morgan Stanley largely see gains remaining intact, with caveats.Goldman attributes the market rise to a stabilization in virus infection rates and an improvement in measures of funding and liquidity stress. The firm has already said that equities price in macroeconomic performance over a two-year time horizon and investors may look past huge economic damage.“Markets will continue to look through bad news about the depth of the economic downturn if they can continue to hold on to their view that a sizable chunk of the recent damage will be reversed by the end of next year,” strategists including Zach Pandl wrote in a note Tuesday.And Morgan Stanley is also comfortable with the disparity between asset price performance and fundamentals, noting that markets tend to lead the economy and care more about rate of changes than absolute levels.“Divergences between the market and economy are common at economic extremes,” wrote strategists including Andrew Sheets in a note Thursday. “Rate of change is key – a ‘U’ shaped recovery is fine, a ‘W’ is not.”For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) investors will be delighted, with the company turning in some strong numbers...

Biopharma shares have outperformed the broader market year-to-date, giving rise to apprehension over whether a pullback is in the offing. An analyst at BofA Securities said Friday that now is the time to go from defensive to offensive in the sector, as quarantines are winding down in several parts of the globe.The Biopharma Analyst Analyst Geoff Meacham shortlisted Eli Lilly And Co (NYSE: LLY), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Bristol-Myers Squibb Co (NYSE: BMY), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Amgen, Inc. (NASDAQ: AMGN) as biopharma stocks where he would put his money to work.The analyst has the following ratings and price targets for the shares: * Lilly: Buy/$165 * Vertex: Buy/$300 * Bristol-Myers Squibb: Buy/raised the price target from $75 to $80 * BioMarin: Buy/lifted price target from $110 to $120 * Amgen: Buy/price target increased from $265 to $2755 Reasons For BofA's Bullish Disposition BofA is increasingly bullish on the biopharma group due to the following factors, Meacham said: * Expectations for robust revenue growth of 6% in the second half of 2020 compared to the first-half, which is double that of the S&P 500's revenue growth. * Reasonable price-earnings for the stocks in the sector. * Many value-creating events lined up for the second half. * Lower policy risk stemming from goodwill earned from the COVID-19 pipeline. * A consistently positive FDA backdrop.Q1 Earnings Get 'A' Grade All of the big biotechs and major pharma companies reported both revenue and adjusted EPS beats in the first quarter, with Lilly and Vertex even raising some parts of their 2020 guidance, Meacham said.Citing slower new starts and forex headwinds, Bristol-Myers Squibb and BioMarin lowered their 2020 revenue guidance, but maintained their EPS guidance, the analyst said. Meacham expressed surprise at Merck & Co., Inc. (NYSE: MRK) and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) lowering their 2020 revenue and adjusted EPS guidance, given his belief that oncology or orphan diseases wouldn't be as sensitive to COVID-19 disruption.See also: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates Lilly One of The Higher Quality Stocks In BofA's Coverage Lilly is a source of differentiated growth given its early product cycle and diversified base business, including diabetes, immunology and immunotoxicology and migraine, and an advancing late-stage pipeline of potentially best-in-class or first-in-class therapies, Meacham said.The analyst said he likes Lily's potential for additional earnings growth in 2020-2021 and views Lilly as one of the higher quality stocks in his coverage despite its higher valuation. The prospects for 2021 look attractive, with selpercatinib potentially launching in non-small cell lung cancer and thyroid cancer by year's end, and tirzepatide approval in 2021 representing a "step change" for the diabetes franchise, he said. Consensus For Vertex To Move Higher? Vertex has a richer -- though well-deserved -- valuation, due to its differentiated growth profile, Meacham said.Given that Vertex's commercial execution is largely unaffected by the COVID-19 pandemic, the analyst said investors will begin to look forward to 2021 sooner than for other companies with more commercial risk.BofA expects consensus estimates to continue to move higher, making Vertex's valuation even more attractive.Bristol-Myers Has Highly Differentiated Growth With an estimated 8% revenue growth and 19% EPS growth in 2021 compared to 5-6% and 12%, respectively, for peers, and with six new launches expected this year, 2020 is shaping up to be a very robust period for Bristol-Myers despite the ongoing COVID-19 headwinds, Meacham said. The analyst said the company's growth looks highly differentiated.An increasingly diversified product mix and beatable launch expectations position the company for meaningful upside to consolidated P&L, with improving synergies, he said. BioMarin's 'Game-Changing' Late-Stage Pipeline BioMarin's late-stage pipeline in valrox and vosoritide have improved its growth outlook, Meacham said.The analyst termed the company's late-stage pipeline as "game-changing." The second-half launch of Roctavian is the most important catalyst for the company this year, with the product likely to accelerate the company's already above-average growth profile, he said. "We see BioMarin as one of the higher quality names in our coverage universe given its clean growth story and it remains our SMid cap top pick." Amgen Looks To New Product Growth To Compensate For Legacy Product Erosion The long-term outlook for Amgen's Otezla is improving given the recently announced Phase 3 data for mild-to-moderate psoriasis, Meacham said.The company rapidly refocused its story from legacy product erosion to new product growth with the acquisition of Otezla from the Bristol/Celgene deal, the analyst said. "Since then Amgen's growth profile has only improved, led by an expanded addressable market for Otezla, outperforming Amgen Biosimilars and Evenity franchises, aggressive formulary negotiation for Aimovig, and an exciting pipeline in AMG 510 and tezepelumab looking to contribute as soon as 2021." The Price Action The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) was last seen trading up 1.25% to 128.76, adding to its 5.6% year-to-date gain. Related Link: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace See more from Benzinga * The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda * The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500 * The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Underpins company plan to expand commercialization and definitive manufacturing relationships

WeeTect, a global leader in designing and manufacturing abrasion resistant helmet visors, today announced that it has started using this technology on other eye and face protection products.

Since its founding in 1965, the California Transit Association (CTA) has been a primary advocate for public transportation in the state.

The Association's team of legislative advocates works to promote multi-year transit funding and to represent transit's interests before the California State Legislature, the Governor and regulatory agencies on the local, state and federal levels.

CTA is dedicated to a collaborative approach to advocating for improved transit operations throughout California. Key to that approach is engaging our members in the advocacy process.

Members are frequently updated on policy developments through a variety of communications processes, and their participation is enlisted in numerous outreach efforts, including personal visits with elected officials, testifying before legislative committees and regulatory agencies, and conducting media relations campaigns.

To cultivate support and increased member activity, the Association strives to strategically mobilize members in key political districts and to build statewide coalitions to focus pressure on policy development.

Of increasing importance is the mobilization of organizations other than transit providers in the
cause.

CTA's partnership with such "non-traditional" transit advocates has supplemented the advocacy effort and has helped members to forge relationships with and utilize the resources of everything from nationwide public interest organizations to local ridership groups.

With support and active engagement from member organizations and other community interests, CTA is focused on implementing transit-friendly policy, a balanced transportation system, and increased transit funding.

Each year, CTA publishes a Legislative Summary that provides a synopsis and analysis of state legislation affecting public transportation and the transit-relevant components of the state budget process.

Compiled by the Association's team of legislative advocates, the annual publication is a great reference tool for those seeking information about statewide transit and transportation legislation.

The report for the 2010 legislative session (31p. PDF) is divided into three catagories:

Significant Transit Legislation: identifying and describing high-priority legislation supported by the Association, pending the Governor's signature in 2010

2010-2011 State Budget: describing the budget's impact on public transportation and the State Transit Assistance (STA) Program, and Proposition 1B allocations

Matrix Of Significant Transit-Related Legislation: Identifying the most significant transit-related legislation considered by the Association's Legislative Committee during the 2010 Legislative Session, whether enacted or not.

Call of Duty: Modern Warfare Chad Michael Collins joins us in the second half of the show this week for an interview about acting in one of the biggest games of the year. That interview starts at 42:04 if you'd like to skip straight to it. In the first half of the show, we give our Modern Warfare campaign and multiplayer impressions, detail a fantastic new program from Microsoft that might help ease the sting out of Scarlett's next-gen launch price tag, discuss Fallout 76's new $100 per year service option, and more!

Apache Spark runs fast, offers robust, distributed, fault-tolerant data objects, and integrates beautifully with the world of machine learning and graph analytics. Learn more here.

Bill Drayton, founder and CEO of Ashoka.

Charles Duhigg, reporter for The New York Times and author of "The Power of Habit: Why We Do What We Do in Life and Business."

Francesca Gino and Adam Grant, of Harvard Business School and Wharton, respectively, discuss their research on gratitude and generosity.

Richard Haass, president of the Council on Foreign Relations, says the U.S. can remain a global leader only if it addresses issues at home.

Gretchen Rubin, author of "Better than Before: Mastering the Habits of Our Everyday Lives," explains that you've got to know your habit-setting style.

Sylvia Ann Hewlett, an economist and the founder of the Center for Talent Innovation, has studied the difference between mentoring and sponsorship and what leaders have to gain from the latter. She says it's important to seek out protégés who outperform, are exceptionally trustworthy, and, most importantly, offer skills, knowledge, and perspectives that differ from your own, so you can maximize the benefits for both parties. Hewlett brings real-world lessons from several successful pairings and tips on how to effectively launch and manage these long-term relationships. She's the author of the book "The Sponsor Effect: How to Be a Better Leader by Investing in Others."

James Clear, entrepreneur and author, says that the way we go about trying to form new habits and break bad ones — at work or home — is all wrong. Many people, he says, focus on big goals without thinking about the small steps they need to take along the way. Just like saving money, habits accrue compound interest: when you do 1% more or different each day or week, it eventually leads to meaningful improvement. So if you’ve made a resolution for the new year or have an idea for how to propel your career forward at any time, these strategies will help. Clear is the author of the book "Atomic Habits: Tiny Changes, Remarkable Results."

Myriam Sidibe, senior fellow at the Harvard Kennedy School, says that brands are uniquely positioned to encourage shifts in consumer behavior that benefit individuals, communities, and the environment. A public health expert, she has studied these types of mission-led marketing campaigns and helped Unilever design one for Lifebuoy soap that not only promoted hand-washing in the developing world but also boosted the business's bottom line. She explains how companies of any size can find the right causes, craft authentic messages, and measure the return on their investments, adding that the current pandemic and economic crisis have made this work even more important. Sidibe is the author of the HBR article "Marketing Meets Mission."

Three recent lawsuits present new challenges for the makers of the Bumbo Baby Sitter, a popular infant chair that are alleged to have caused a number of injuries after babies fell from the seats.

Federal and state tax credits and incentives can help fund new business ventures and offset project expenses, saving your company time and money. Whether your company is adding jobs, investing in new technology or expanding its footprint to additional locations, there are credits designed to help fund these projects. Below we have outlined relevant tax...

The post A Guide to Tax Credits and Incentives for Missouri Businesses appeared first on Anders CPA.

There is a great opportunity for government contractors to save on sales or use taxes paid for consumables used on government contracts. The U.S. Government is not subject to sales/use tax, however, government contractors typically pay tax on their consumable purchases. Government contractors may be paying tax on many of their overhead purchases needlessly. Sales...

The post Reverse Audits for Government Contractors appeared first on Anders CPA.

Reuters

• Elon Musk says Tesla may leave its Palo Alto headquarters and Fremont, California factory. 
• In a tweet Saturday morning, the chief executive continued his outrage against shelter-in-place orders that have forced most non-essential businesses to close. 
• Last week, Musk likened the rules to fascism, and urged leaders to "give people their goddamn freedom back." 
• Visit Business Insider's homepage for more stories.

After a week of decrying coronavirus shelter-in-place orders that have left Tesla's main factory shuttered and unable to produce vehicles, Elon Musk says the company may move its factory out of the state.

"Tesla is filing a lawsuit against Alameda County immediately," the chief executive said on Twitter Saturday morning. "The unelected & ignorant 'Interim Health Officer' of Alameda is acting contrary to the Governor, the President, our Constitutional freedoms & just plain common sense!"

See the rest of the story at Business Insider

NOW WATCH: How waste is dealt with on the world's largest cruise ship

See Also:

• Tesla has secured a $565 million loan for its factory in Shanghai where the company just halted operations
• Elon Musk and Grimes gave their baby an unusual name with multiple hidden meanings, and it may have a hidden connection to the X-Men
• Watch Elon Musk pronounce his baby's name, which he says Grimes mostly picked out

EA is taking its usual E3-adjacent festivities online through EA Play Live, set to be held during the gap in mid-June left by E3†™s COVID-19-driven cancellation. ...

The Tax Cuts and Jobs Act is changing the way organizations do business, including not-for-profit organizations. To help you prepare for the changes and take advantage of new benefits, the Anders Not-for-Profit Group has compiled a chart on the most… Read More

The post Tax Reform: Impact on Not-for-Profits appeared first on Anders CPAs.

Working within a tight budget can cause some not-for-profit organizations to neglect their financial reporting. Office managers may be assigned to do the bookkeeping, but don’t have the time or expertise to do the technical accounting. Having accounting and financial… Read More

The post How Not-for-Profits Can Focus on the Mission, Not the Financials appeared first on Anders CPAs.

Many not-for-profits organizations have been concerned about the taxability of parking and transportation benefits as a result of the Tax Cuts and Jobs Act. Fortunately, the IRS recently issued interim guidance around the treatment of these benefits incurred after December… Read More

The post How Not-for-Profits Can Take Advantage of New Guidance on Taxable Parking Benefits by March 31, 2019 appeared first on Anders CPAs.

The Tax Cuts and Jobs Act (TCJA) significantly changed the tax benefits of donating to your favorite charity starting in 2018. Now that we’ve seen a full year with the new provisions, not-for-profit organizations are taking a look at the… Read More

The post Charitable Giving is Down Following Tax Reform: How Not-for-Profits Should React appeared first on Anders CPAs.

Many not-for-profits organizations have been concerned about the taxability of parking and transportation benefits as a result of the Tax Cuts and Jobs Act. Fortunately, Congress recently moved to repeal the dreaded “parking tax” on fringe benefits, such as free… Read More

The post Unpopular Parking Tax on Not-for-Profits May Be Repealed appeared first on Anders CPAs.

On March 26, 2020, the Senate passed “Phase III” of the Coronavirus Response Package, the Coronavirus Aid, Relief, and Economic Security (CARES) Act in a 96-0 vote.

Monster Hunter publisher Capcom reported Friday a year on year decline in annual sales, but a jump in profits for its full fiscal year. ...

The IRS recently released guidance on the CARES Act employment tax deposit deferral. Below are the highlights of the deferral, including eligibility, timeline and use with other incentives.
Deferral Eligibility
The CARES Act allows employers to defer deposits and payments… Read More

The post IRS Defers Employment Tax Deposits and Payments Through 2020 appeared first on Anders CPAs.

Business owners, whether they are owners of startup businesses or mature businesses, are always thinking about how to enhance their company’s value. Startups are particularly focused on the value of their company for capital raising purposes. One advantage a startup… Read More

The post Ten Ways a Startup Can Enhance Its Value appeared first on Anders CPAs.

Monster Hunter publisher Capcom reported Friday a year on year decline in annual sales, but a jump in profits for its full fiscal year. ...

RavenCSI "Pro" plan - a leading survey tool for business intelligence capture, to be offered at no cost through the end of 2020